Andrew Wang

Dr. Andrew Wang is a physician-scientist and Associate Professor in the Department of Radiation Oncology at the University of North Carolina (UNC) School of Medicine. He is the Director of Clinical and the co-Director of the T32 Carolina Cancer Nanomedicine Training Program. Dr. Wang also holds adjunct positions in the Department of Urology, Department of Biomedical Engineering, and the Molecular Therapeutics Program in the School of Pharmacy. Dr. Wang obtained his MD from the Harvard-MIT Health Sciences Technology program at Harvard Medical School. He then completed clinical oncology training in the Harvard Radiation Oncology Program. During residency, Dr. Wang completed a postdoctoral Fellowship under the dual mentorship of Prof. Robert Langer at MIT and Dr. Farokhzad at BWH. Dr. Wang's research is focused on the application of nanotechnology to improve cancer management. Dr. Wang is acting CEO and cofounder of Capio Biosciences Inc. and has been collaborating with Dr. Hong on the clinical translation of CapioCyte™ CTC technology for the past 3 years. Their collaboration has resulted in exciting preliminary data which has resulted in two manuscripts that are currently under review as well as a patent application.